The purpose of this trial is to compare, within current guidelines (GL) and instructions for use (IFU), an abbreviated versus a prolonged DAPT duration after bioresorbable polymer coated Ultimaster sirolimus-eluting stent implantation in patients presenting HBR features.
The Principal Investigators are Marco Valgimigli (Switzerland) and Peter Smits (The Netherlands).
The European Cardiovascular Research Institute (ECRI) acts as sponsor for the MASTER DAPT trial. ECRI is being supported by a scientific grant from Terumo.
The MASTER DAPT trial is registered at clinicaltrials.gov: